

PRV

PATENT- OCH REGISTRERINGSVERKET

Patentavdelningen

REC'D	21 FEB 2005
WIPO	PCT

**Intyg
Certificate**

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

(71) *Sökande* LTP Lipid Technologies Provider AB, Karlshamn SE
Applicant (s)

(21) *Patentansökningsnummer* 0400233-3
Patent application number

(86) *Ingivningsdatum* 2004-02-04
Date of filing

Stockholm, 2005-02-09

För Patent- och registreringsverket
For the Patent- and Registration Office

Gunilla Larsson

*Avgift
Fee*

**PRIORITY
DOCUMENT**
 SUBMITTED OR TRANSMITTED IN
 COMPLIANCE WITH RULE 17.1(a) OR (b)

RECTAL COMPOSITION

Ink. t. Patent- och reg.verket

2004-02-04

FIELD OF THE INVENTION

Huvudboxen Kestan

5 The present invention relates to a composition for rectal administration for the treatment of constipation, a method for its preparation, and its use.

BACKGROUND OF THE INVENTION

10

Constipation is often defined as a frequency of defecation of twice per week or less but frequency is not the only sufficient criterion. Most individuals who describe them as constipated complain of excessive straining or discomfort at 15 defecation or passage of hard or pellet stools, although the frequency of defecation is within the normal range (A Wald, *Constipation*. *Adv Gastroenterol* 2000;84(5):1231-1246).

20 Constipation is a serious problem affecting many people. In the United States about a fourth of elderly men and a third of elderly women are affected (D C Schaeffer and L J Cheskin, *Constipation in the Elderly*. *Am Fam Physician* 1998;58(4):907-914). At least 75 per cent of elderly hospitalized patients and nursing home residents use laxatives for bowel regulation 25 (W R Primrose et al., *Prescribing patterns observed in registered nursing homes and long-stay geriatric wards*. *Age Ageing* 1987;16:25-28).

30 While a diet rich in natural fiber and physical activity may alleviate and even prevent constipation, this is not true or possible for various reasons for a large number of affected persons. The use of laxatives thus is the remedy most often relied on to fight constipation. They are however not free of drawbacks, such as a substantial delay between administration 35 and onset of effect or irritation of the bowel when used over

Huvudläkaren Kasson

a long period of time. Another way to treat constipation is by enemas. A drawback with enemas is that their administration is problematic for reasons of leakage.

5 OBJECTS OF THE INVENTION

It is an object of the present invention to provide a means for treating constipation that is efficient and has a rapid onset of action, does not irritate the mucus of the bowel, and is convenient to administer.

Further objects of the invention will be understood from the following description of the invention and preferred embodiments thereof as well as from the appended claims.

15

SUMMARY OF THE INVENTION

According to the present invention is disclosed a pharmaceutical composition for the treatment of constipation by rectal administration comprising a polar lipid component, an oily triglyceride component, a polyvalent alcohol component, and water.

It is preferred for the triglyceride oil component to be a fraction of natural triglyceride, in particular a vegetable oil. The term "oily triglyceride component" relates to triglyceride of oily consistence at a temperature of 20°C. The term triglyceride includes mixtures of triglycerides.

It is preferred for the polar lipid component to consist of polar lipid, the polar lipid being preferably galactolipid, even more preferred digalactosyldiacylglycerol. In this application the term polar lipid comprises a mixture of polar lipids; the term galactolipid comprises a mixture of galactolipids.

It is preferred for the polyvalent alcohol component to comprise one or more of glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, butylene-1,4-diol, pentylene-1,5-diol, hexylene-1,6-diol, and macrogol.

5 Particularly preferred are glycerol and propylene glycol. Most preferred is glycerol.

It is particularly preferred for the pharmaceutical composition of the invention to comprise from 0 per cent to 30 per cent of oily triglyceride, from 3 to 30 per cent of polar lipid component, more preferred from 5 per cent to about 25 per cent, most preferred from about 10 per cent to about 20 per cent.

15 According to a first preferred aspect the pharmaceutical composition of the invention is of a creamy consistence and comprises from 5 to 30 per cent of oily triglyceride.

According to a second preferred aspect the pharmaceutical 20 composition of the invention is of a gellous or viscous consistence and comprises from 5 per cent to 30 per cent of polar lipid component, more preferred from 8 per cent to about 25 per cent, most preferred from about 10 per cent to about 20 per cent, while it is free from oily triglyceride.

25 According to a third preferred aspect the pharmaceutical composition of the invention comprises from 5 per cent to 75 per cent of polyvalent alcohol component, more preferred from 8 per cent to 70 per cent, most preferred from about 10 per cent to about 70 per cent.

According to a fourth preferred aspect the pharmaceutical composition of the invention essentially consists of from 8 to 30 per cent of galactolipid, from 8 to 75 per cent of

0046 8 6899510

4

Ink. t. Patent- och reg.verket

2004-02-04

glycerol, and from 20 to 75 per cent of water, with ~~the~~ ^{Hveddskassen} proviso that said components add up to 100 per cent.

According to a fifth preferred aspect the pharmaceutical
5 composition of the invention has a dynamic viscosity at 20°C
of at least $\eta \cdot 10^{-3}$ Ns/m², η being 2.5 or more, preferably about
4 more, more preferred about 9 or more, most preferred about
30 or more.

10 The composition of the invention may additionally contain one
or more of colourant, preservative, fragrance, UV-stabilizing
agent, antioxidant or similar.

According to the invention is also disclosed a device, such as
15 a disposable syringe, filled with a single dose of the
composition of the invention. The amount of composition in the
device may vary within wide limits but will preferably be from
5 to 30 ml, more preferred from 10 to 20 ml. It is also
possible to provide the single dose in a plastic bag provided
20 with a sealed mouthpiece which is removed prior to use, from
which it can be squeezed out for rectal administration. The
invention also comprised a method of manufacture of the
device, comprising providing the composition of the invention,
providing a compressible container with a mouthpiece suited
25 for rectal administration, filling the container with a single
dose of the composition of the invention, and sealing the
container and/or the mouthpiece. It is understood that the
space in the container filled with the composition and the
mouthpiece are in communication. The mouthpiece tip must be
30 sealed either before or after filling with a seal that can be
removed prior to administration. The seal may also have the
form of a breakable mouthpiece tip provided by an indication
of fracture. For rectal administration of the composition of
the invention also conventional plunger type, positive-
35 displacement syringes with a short and wide nozzle may be

used. A nozzle diameter of, for instance, 12 mm and more is suitable. The nozzle is provided with a bulbous end to which a flexible plastic tube of corresponding diameter and a non-critical length of about 20 cm is connected for insertion into the rectum. Also disclosed is the aforementioned compressible device filled with a single dose of the composition of the invention. According to the invention is also disclosed a method of manufacture of the aforementioned device, comprising providing the composition of the invention, providing a compressible container with a mouthpiece suited for rectal administration, filling the container with a single dose of the composition, and sealing the container and/or the mouthpiece.

15 A single dose of the composition of the invention can be administered by rectal injection within a rather short period of time, such as from 5 to 60 seconds.

20 The composition of the invention of a gelous consistence or the consistence of highly viscous liquid, which is free from oily triglyceride, can be prepared by mixing the polar lipid component and the polyvalent alcohol component, followed by the addition of water mixing. Air bubbles enclosed in the composition can be removed by centrifugation. The composition is allowed to stand for a selected period of time, such as 12 hours or more, to complete solvation (swelling) of the polar lipid component. Swelling is facilitated by a short treatment with a high-shear mixer or similar high-shear agitation.

25

30 The composition of the invention of a creamy consistence comprising oily triglyceride can be prepared by separately mixing the galactolipid and fractionated oat oil components, and the polyvalent component and water, respectively. The thus formed oil and aqueous phases are heated, such as to a

35 temperature of about 65° C to 70°C. The warm oil phase is then

5 poured into the warm aqueous phase while mixing at a high shear rate. The thus formed pre-emulsion is further homogenized in a warm state. After cooling to room temperature, the composition has the form of a smooth, viscous cream.

10 According to a sixth preferred aspect of the invention is disclosed a method of treating constipation, the method comprising rectal administration of a constipation-dissolving amount, such as from 5 to 50 ml, of the composition of the invention to a person suffering from constipation.

15 According to a seventh preferred aspect of the invention is disclosed the therapeutic use of the composition of the invention, in particular the use for treating constipation.

20 According to an eighth preferred aspect of the invention is disclosed a method for the manufacture of a medicament for treating constipation, the method comprising blending a polar lipid component, a polyvalent alcohol component, water and, optionally, an oily triglyceride, to form a gellous or viscous solution.

25 According to a ninth preferred aspect a pharmacologically active agent can be incorporated in the composition of the invention by dissolution or suspension. Particularly preferred for such incorporation are agents that are known to be administered per rectum, such as sulphasalazine, 5-amino-salicylate, sodium aminosalicylate, diazepam, chlorpromazine, 30 tramadol, morphine, domperidone, piroxicam, paracetamol, indomethacin, diclofenac, naproxen, metronidazole, antibiotics and antimycotics but also local anaesthetics for use in hemorrhoid treatment such as lidocaine. The thus modified composition can be used for rectal administration of the 35 pharmacologically active agent.

According to the invention is also disclosed the use of the composition of the invention for treating constipation.

5 Also disclosed is the use of the composition for rectal administration of a pharmacologically active agent. Furthermore, according to the invention, is disclosed a method of manufacture of a medicament for treating constipation, comprising blending a polar lipid component, a polyvalent 10 alcohol component, water and, optionally, an oily triglyceride, to form a gellous or viscous solution.

The composition of the invention is remarkably physically stable. Depending on its composition its consistence may be 15 that of a cream, a gel or a highly viscous liquid. Its consistence or viscosity is only moderately affected by a change in temperature; for example, it can be transferred directly from the refrigerator (at 4°C) to a syringe for administration and administered to a patient at that 20 temperature.

The invention will now be explained in greater detail by reference to preferred but not limiting embodiments thereof.

25 DESCRIPTION OF PREFERRED EMBODIMENTS

EXAMPLE 1

30 General method of preparation of the composition of the invention of gellous consistence or of the consistence of a viscous liquid. 20.0 g of galactolipid (CPL®-Galactolipid; Lipid Technologies Provider AB, Karlshamn, Sweden) and 20.0 g of glycerol were mixed by hand in a plastic container and allowed to stand for 30 min. Water (60 ml) was added and the 35 contents were again mixed by hand and left over night at room

temperature. After repeating the mixing by hand the mixture was centrifuged 10 min at 1500 rpm using a Jouan bench centrifuge to remove air bubbles. Mixing and centrifugation was repeated once. The resulting formulation was a clear 5 viscous gel, which can be stored at room temperature or in a refrigerator. By lowering the amount of galactolipid below about eighth percent by weight, a viscous liquid is obtained; it is prepared in the same manner as described above.

10 EXAMPLE 2

General method of preparation of the composition of the
invention of a creamy consistence. Fractionated oat oil (10 g; 15 Lipid Technologies Provider AB, Karlshamn, Sweden) and corn oil (10 g) were mixed in a beaker and then stirred with a magnetic stirrer for 30 min when the galactolipid had dispersed completely to form an oil phase. Glycerol (40 g) and water (40 ml) were mixed in a second beaker to form an aqueous phase. The oil and aqueous phases were heated to 65°C to 70°C, 20 and the warm oil phase was poured into the warm aqueous phase during high-shear mixing (Polytron PT-MR 3000). After the end of addition mixing was continued for 2 min at 15,000 rpm. The pre-emulsion thus formed was homogenized twice at 200 psi in an ultrasonic homogeniser (Branson Minisonic 4). The product 25 was allowed to cool in a water bath. It had the form of a smooth viscous cream.

EXAMPLE 3

30 Preparation of compositions of the invention. A number of compositions according to the invention listed in Table 1 were prepared by the general methods of Examples 1 and 2 in varying batch sizes. A gelous composition (A) for rectal administration which is not a composition of the invention is 35 also shown.

Table 1. Compositions of the invention (Nos. 1-23)

Comp. No.	Components (per cent by weight)			Batch size (g)	Appearance
	Galactolipid	Glycerol or PG**) or BD***)	Water		
1	20	55	25	343	Clear yellow-brown gel
2	20	50	30	200	Clear yellow-brown gel
3	20	50	30	50	Clear yellow-brown gel
4	20	30	50	50	Clear yellow-brown gel
5	15	50	35	50	Clear yellow-brown gel
6	15	35	50	50	Clear yellow-brown gel
7	10	50	40	100	Clear yellow-brown gel
8	15	53	32	100	Clear yellow-brown gel
9	10	50	40	100	Clear yellow-brown gel
10	15	45	40	100	Clear yellow-brown gel
11	10	50	40	100	Clear yellow-brown gel
12	20	30	50	100	Clear yellow-brown gel
13	20	10	70	100	Clear yellow-brown gel
14	20	20	60	100	Clear yellow-brown gel
15	20	30	50	100	Clear yellow-brown gel
16	20	40	40	100	Clear yellow-brown gel
17	20	55	25	100	Clear yellow-brown gel
18	10	40	40	100	+ 10% FOO; yellow-brown cream
19	5	55	40	100	Opaque yellow-brown viscous liquid
20	5	25	70	100	Slightly milky yellow-brown viscous liquid
21	5	55	40	100	Opaque yellow-brown viscous liquid
22	5	75	20	100	Nearly clear yellow-brown viscous liquid
23	5	5	90	100	Milky yellow-brown viscous liquid
24	10	20 PG	70	50	Semi-clear yellow-brown viscous liquid
25	18	30 PG	52	50	Semi-clear yellow-brown viscous liquid
26	20	30 BD	50	50	Milky yellow-brown viscous liquid
27	10	10 BD	80	50	Semi-clear yellow-brown viscous liquid
A*)	-	-	89	100	Milky yellow-brown gel

5 *) Comprises additionally 10 per cent of fractionated oat oil (FOO; non-polar triglyceride oil) and 1 per cent of Carbopol 974P, a cross-linked polyacrylic acid marketed by Noveon Inc., Cleveland, Ohio, USA)

*) Propylene glycol

****) 1,3-butanediol

10 EXAMPLE 4

Comparative test of constipation-releasing effect. Composition no. 1 (Table 1), which is a composition of the invention, was compared with composition A (Table 1), which is a gelous composition of similar physical appearance but substantially different from and thus not comprised by the composition of the invention. In this test three healthy persons compared the

aforementioned gellous compositions in regard of their efficiency to trigger the need for rectal emptying. The results are shown in Table 2. In assessing the various variables the test persons used a scale from 0 to 10 where 0 signifies best and 10 worst in regard of volume, irritation and viscosity of/caused by the respective preparation, and where 0 signifies worst and 10 best in regard of effect. The test was carried out in the following manner. The tip of the syringe containing 10 g of the preparation was inserted into the rectum until a stop was felt. Then the sample was injected. The test person was told to stand up and walk around for one min and then to sit down for 15 min. After an interval of two hours the test person carried out the same procedure with the other formulation.

15

Table 2. Comparison of constipation-releasing effect

Composition	Test person	Volume of composition	Irritation caused by composition	Viscosity of composition	Time from administration to toilet visit (min)	Effect	Difficulty of keeping composition for 15 min
1	1	0	0	0	5	10	yes
	2	0	0	0	5	10	yes
	3	0	0	0	5	10	yes
F	1	0	0	0	15	5	no
	2	0	0	0	60	4	no
	3	0	0	0	15	3	no

EXAMPLE 5

20

Preparation of the composition of the invention comprising a pharmacologically active agent

25

Lidocaine composition. 0.20 g of lidocaine hydrochloride (Sigma-Aldrich, L5647) was added to 9.80 g of composition no. 16 (Table 1) and mixed gently by hand. The resulting composition was a milky yellow-brown viscous liquid.

5-Aminosalicylic acid composition. 0.50 g of powderous 5-aminosalicylic acid, 95 % (Sigma-Aldrich, A79809) was suspended in 37.0 g of warm (50°C) water using a magnetic stirrer. 3.0 g of glycerol was added to the suspension, followed by the addition of 10.0 g of galactolipid in two portions. The mixture was stirred using a spatula and was then left over night at room temperature (21°C). The resulting composition was a brown highly viscous suspension.

10

Both compositions were easily administered rectally from a syringe.

EXAMPLE 6

15

Viscosity measurements

The dynamic viscosity at 20°C of compositions no. 20 and no. 20 23 (Table 1) representing compositions near the low end of the useful viscosity range was estimated in the following way. A 5 ml volume pipette was clamped in an upright position and filled with sample up to the volume mark, and was then allowed to drain. The time for draining to a mark 10 cm below the volume mark was recorded. Pure water was used as a reference.

It was assumed that the tested compositions of the invention behaved as Newtonian fluids. Their viscosity was calculated using the equation $\eta_{sample} = \eta_{water} \cdot \rho_{sample}/\rho_{water} \cdot t_{sample}/t_{water}$. 30 The densities for 5 % and 25 % by weight of glycerol in water at 20°C, 1.010 and 1.059 kg/dm³ calculation (Handbook of Chemistry and Physics, 60th Ed.), respectively, were substituted in the equation for the unknown density of compositions no. 23 and 20, respectively. The other constants 35 used were $\rho_{water} = 0.998 \text{ kg/dm}^3$ and $\eta_{water} = 1.00 \times 10^{-3} \text{ Ns/m}^2$ (1 cP).

0046 8 6899510

12

Ink t. Patent- och registreringsverket

2004-02-04

Huvudfoxeri Kassan

The following t_{sample} values were recorded at 20°C: water, 5 s;
composition no. 23, 19 s; composition no. 20, 42 s. The
dynamic viscosity of composition 20, containing 5 % of
galactolipid and 25 % of glycerol, was calculated to be
5 $8.9 \cdot 10^{-3}$ Ns/m², and that of composition no. 23, containing
5 % galactolipid and 5 % glycerol, to be $3.8 \cdot 10^{-3}$ Ns/m².

Claims

Huvudforskan Rassan

1. Pharmaceutical composition for the treatment of constipation by rectal administration comprising a polar lipid component, a polyvalent alcohol component, water, and optionally an oily triglyceride.
2. The composition of claim 1, wherein the oily triglyceride component is a fraction of natural triglyceride.
3. The composition of claim 2, wherein the oily triglyceride component comprises fractionated oat oil.
4. The composition of any of claims 1-3, wherein the polar lipid component comprises galactolipid.
5. The composition of claim 4, wherein the galactolipid comprises digalactosyldiacylglycerol.
6. The composition of any of claims 1-5, wherein the polyvalent alcohol component is selected from of glycerol, propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, butylene-1,4-diol, pentylene-1,5-diol, hexylene-1,6-diol, macrogol, and their mixtures.
7. The composition of claim 6, wherein the polyvalent alcohol component is glycerol.
8. The composition of claim 6, wherein the polyvalent alcohol component is propylene glycol.
9. The composition of any of claims 1-8, comprising from 0 per cent to 30 per cent of oily triglyceride and from 3 to 30 per cent of polar lipid component.

10. The composition of any of claims 1-9 of a creamy consistence, comprising from 5 to 30 per cent of oily triglyceride.
- 5 11. The composition of any of claims 1-9 of a gelous or viscous consistence, comprising from 5 per cent to 30 per cent of polar lipid component, with the proviso that it is free from oily triglyceride.
- 10 12. The composition of claim 11, comprising from 8 per cent to 25 per cent of polar lipid component.
13. The composition of claim 11, comprising from 10 per cent to 20 per cent of polar lipid component.
- 15 14. The composition of any of claims 11-14, comprising from 5 per cent to 75 per cent of polyvalent alcohol component.
- 15 15. The composition of any of claims 11-14, comprising from 8 per cent to 70 per cent of polyvalent alcohol component.
16. The composition of any of claims 11-14, comprising from, 10 per cent to 70 per cent of polyvalent alcohol component.
- 25 17. The composition of claim 11, essentially consisting of from 8 to 25 per cent of galactolipid, from 8 to 75 per cent of glycerol, and from 20 to 75 per cent of water, with the proviso that said components add up to 100 per cent.
- 30 18. The composition of any of claims 1-17 comprising a pharmacologically active agent.
19. The composition of claim 18, wherein the pharmacologically active agent is selected from sulphasalazine, sodium aminosalicylate, diazepam, chlorpromazine, tramadol, morphine,

Huvudfakten kasson
domperidone, piroxicam, paracetamol, indomethacin, diclofenac,
naproxen, metronidazole, antibiotics, antimycotics, local
anaesthetics for use in hemorrhoid treatment such as
lidocaine..

5

20. The composition of any of claims 1-19, comprising one or
more of colourant, preservative, perfume, UV-stabilizing
agent, antioxidant.

10 21. The composition of any of claims 1-20 having a dynamic
viscosity at 20°C of at least $2.5 \cdot 10^{-3}$ Ns/m².

22. The composition of any of claims 1-20 having a dynamic
viscosity at 20°C of at least about $5 \cdot 10^{-3}$ Ns/m².

15

23. The composition of any of claims 1-20 having a dynamic
viscosity at 20°C of at least about $9 \cdot 10^{-3}$ Ns/m².

30 or more.

20 24. Compressible device filled with a single dose of the
composition of any of claims 1-23 provided with a sealed
mouthpiece adapted for rectal administration.

25 25. The device of claim 24 in form of a syringe.

25

26. The device of claim 24 in form of a soft plastic
container.

27. The device of any of claims 24-26, wherein the single dose
30 has a volume of from 5 to 50 ml.

28. A method of treating constipation, comprising rectal
administration of a constipation-dissolving amount of the
composition of any of claims 1-23 to a person suffering from
35 constipation.

0046 8 6899510

Ink t Patent- och registrer

16

2004-02-04

Huvudforskrift Kassan

29. A method of manufacture of the device of any of claims 24-
27, comprising providing the composition of any of claims 1-
23, providing a compressible container with a mouthpiece
5 suited for rectal administration, filling the container with a
single dose of said composition, and sealing the container
and/or the mouthpiece.

30. Use of the composition of claims 1-23 for treating
10 constipation.

31. Use of the composition of claim 18 or 19 for rectal
administration of a pharmacologically active agent.

15 32. A method of manufacture of a medicament for treating
constipation, comprising blending a polar lipid component, a
polyvalent alcohol component, water and, optionally, an oily
triglyceride, to form a gelous or viscous solution.

20

25

30

17

Ink. t. Patent- och reg. verket

ZK 67 04

A b s t r a c t

Huvudfrågan Kosson

A viscous or gelous pharmaceutical composition for the treatment of constipation by rectal administration comprises a 5 polar lipid component, a polyvalent alcohol component, water, and optionally an oily triglyceride. Also disclosed is a compressible device filled with a single dose of the composition and a method for its manufacture; a method of treating constipation, comprising rectal administration of a 10 constipation-dissolving amount of the composition; and a method of manufacture of a medicament for treating constipation comprising the composition of the invention.

15